anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A method is provided to check the effect of a skin care treatment product by analyzing the digital image of a skin. CONSTITUTION: A digital image, which captures a skin region, is obtained by using a white calibration standard under an orthogonally polarized light condition. A skin analysis process is executed by using the digital image. A skin care product is spread on the same skin region for an effective time. The skin analysis process is executed by using the following digital image of the skin region. The reduction of the skin erythema is determined by comparing the intensity maps of the digital images.
Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill malignant diseased cells, but also participate in the regulation of immune cell response and play a role in a variety of tumor immunotherapy strategies. The 2-year survival rate of NK cells combined with stem cell therapy for patients with hematological malignancies reached 36%, which is significantly higher than the 2-year survival rate (about 15%) of stem cell therapy alone, which can extend the disease-free survival period of leukemia patients by an average of 1.5 years. Relapsed and refractory leukemia can achieve a complete remission rate of up to 40%. However, NK cell therapy alone or the use of autologous NK cells to treat solid tumors is not effective. In clinical trials related to rectal cancer, esophageal cancer, kidney cancer, and gastric cancer, the clinical response of NK cell adoptive therapy is not good. A phase II clinical study found that the disease control rate of patients with ovarian cancer and breast cancer after radiotherapy and chemotherapy can reach about 60% by NK cell infusion. The main reason for the low treatment efficiency of solid tumors is related to the immunosuppressive effect of the tumor microenvironment. Combination therapy is a potential breakthrough. Researches targeting tumor immune microenvironment, targeting tumor cells and combined with NK cell therapy have shown tumor therapeutic potential. NK cells combined with IgG1 antibody treatment of gastric cancer and colon cancer in about 50% of patients with partial remission, and 17% of patients are in stable condition. In summary, the combined application of the demethylation drug DAC and NK cell infusion may be a new clinical strategy for the treatment of malignant tumors.
PURPOSE:The titled enriching agent is composed mainly of a product obtained by decreasing the NaCl content of sea-water as far as possible by desalting sea- water, and sterilizing the desalted product. CONSTITUTION:Sea-water is desalted e.g. with an ion-exchange membrane to decrease the NaCl content in the sea-water as far as possible, preferably <=8,000 mg/l. The desalted sea-water is concentrated or dried or diluted, and then sterilized, and is used as a main component of the titled agent. If necessary, one or more kinds of vitamins, saccharides, and proteins are added to the product to obtain a mineral nutrient enriching agent. It is necessary to take care of avoiding the excessive taking of NaCl considering the NaCl content of the agent. The agent is especially effective to heavily perspired person such as sportman, laborer, etc., especially for the supply of nutrient to a sport player, heavy worker, etc.
Plant submergence is a major abiotic stress that impairs plant performance. Under water, reduced gas diffusion exposes submerged plant cells to an environment that is enriched in gaseous ethylene and is limited in oxygen (O2) availability (hypoxia). The capacity for plant roots to avoid and/or sustain critical hypoxia damage is essential for plants to survive waterlogging. Plants use spatiotemporal ethylene and O2 dynamics as instrumental flooding signals to modulate potential adaptive root growth and hypoxia stress acclimation responses. However, how non-adapted plant species modulate root growth behaviour during actual waterlogged conditions to overcome flooding stress has hardly been investigated. Here we discuss how changes in the root growth rate, lateral root formation, density, and growth angle of non-flood adapted plant species (mainly Arabidopsis) could contribute to avoiding and enduring critical hypoxic conditions. In addition, we discuss current molecular understanding of how ethylene and hypoxia signalling control these adaptive root growth responses. We propose that future research would benefit from less artificial experimental designs to better understand how plant roots respond to and survive waterlogging. This acquired knowledge would be instrumental to guide targeted breeding of flood-tolerant crops with more resilient root systems.
Part A: Ascending doses of AZD5363 administered orally, twice daily, on a 7-day repeating regimen (4 days on, 3 days off and 2 days on, 5 days off), to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A (4 days on, 3 days off and 2 days on, 5 days off). Part C and D: AZD5363 orally, twice daily on an intermittent regimen (4 days on, 3 days off).
The reported rate of the occurrence of unilateral spatial neglect (USN) is highly variable likely due to the lack of validity and low sensitivity of classical tools used to assess it. Virtual reality (VR) assessments try to overcome these limitations by proposing immersive and complex environments. Nevertheless, existing VR-based tasks are mostly focused only on near space and lack analysis of psychometric properties and/or clinical validation. The present study evaluates the clinical validity and sensitivity of a new immersive VR-based task to assess USN in the extra-personal space and examines the neuronal correlates of deficits of far space exploration. The task was administrated to two groups of patients with right (N = 28) or left (N = 11) hemispheric brain lesions, also undergoing classical paper-and-pencil assessment, as well as a group of healthy participants. Our VR-based task detected 44% of neglect cases compared to 31% by paper-and-pencil tests in the total sample. Importantly, 30% of the patients (with right or left brain lesions) with no clear sign of USN on the paper-and-pencil tests performed outside the normal range in the VR-based task. Voxel lesion-symptom mapping revealed that deficits detected in VR were associated with lesions in insular and temporal cortex, part of the neural network involved in spatial processing. These results show that our immersive VR-based task is efficient and sensitive in detecting mild to strong manifestations of USN affecting the extra-personal space, which may be undetected using standard tools.
BACKGROUND: Early infantile epileptic encephalopathy 25 (EIEE25) is a distinct type of neonatal epileptic encephalopathy caused by autosomal recessive mutations in the SLC13A5 gene. SLC13A5 encodes a transmembrane sodium/citrate cotransporter required for regulating citrate entry into cells.
METHODS: Four families with recessively inherited epileptic encephalopathy were sequenced by clinically accredited laboratories using commercially available epilepsy gene panels. Patients were examined by a neurologist and were clinically diagnosed with infantile epileptic encephalopathy.
RESULTS: We present four families with global developmental delay, intellectual disability, and defective tooth development with four novel homozygous mutations in SLC13A5. The neurological examination showed spastic quadriplegia with increased deep tendon reflexes. Brain magnetic resonance imaging showed nonspecific signal abnormality of the bilateral hemispheric white matter. Despite similar clinical features, the conditions were based on different molecular mechanisms acting on SLC13A5 (abnormal splicing, large-scale deletions, and tandem-residue insertion).
CONCLUSIONS: Our results extend the landscape of autosomal recessive inherited homozygous mutations in SLC13A5 that cause a distinctive syndrome of severe neonatal epileptic encephalopathy. Our observations confirm the homogeneity of epileptic encephalopathy and dental abnormalities as a distinct clinical marker for EIEE25 despite the heterogeneous functional and mutational background.
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered as variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline "Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)" was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and of patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical specialties involved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. The second part is concerned with the topics of supportive therapy in the acute phase of EN and outpatient follow-up treatment.
Supportive efficacy and safety data were provided from Study 4, which was a multicenter, open-label, two-phase study in patients aged 2 to 17 years of age with polyarticular juvenile idiopathic arthritis (pJIA) diagnosed according to American College Rheumatology (ACR) classification criteria who had an inadequate response to current therapy. This study was divided into a dose range finding portion and a confirmatory portion. Three doses were investigated in the 12-week core treatment phase of the dose range finding portion. Following the dose selection, patients were enrolled to receive the recommended dose [3 mg/kg every 2 weeks (q2w) in 42 patients weighing ≥30 kg (Group A) and 4 mg/kg q2w in 31 patients weighing ≥10 kg and <30 kg (Group B)]. A total of 101 patients were treated, including 73 patients who received the recommended dose regimen from baseline and 20 patients who had their dose switched to the recommended dose during the study. Of the 73 patients who received the recommended dose throughout treatment, baseline mean disease duration was 2.48 years and a JADAS-27 score of 22.73. At baseline, 84.9% of patients had received at least one conventional DMARD (mainly methotrexate), 13.7% received systemic glucocorticoids, and 19.2% had prior treatment with biological DMARDs (mainly TNF antagonists). The patients treated had subtypes of JIA that, at disease onset, included rheumatoid factor positive (17.8%), negative polyarticular JIA (65.8%), or extended oligoarticular JIA (16.4%).

Use of KEVZARA in pediatric patients with pJIA is supported by evidence from adequate and well-controlled studies of KEVZARA in adults with RA, pharmacokinetic data from adult patients with RA, and pharmacokinetic (PK) comparability from Study 4 [see Clinical Pharmacology (12.3)].
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro and in vivo studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions. Specifically, there are no pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between pregabalin and commonly used antiepileptic drugs [see CLINICAL PHARMACOLOGY (12)].

Pharmacodynamics

Multiple oral doses of pregabalin capsules were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when pregabalin was co-administered with these drugs. No clinically important effects on respiration were seen.
Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods.
The invention provides seafood-marinade uncongealed beancurd, and relates to a soy food and a making method thereof. The making method is characterized by comprising the following: a step of preparing seafood marinade, which is to prepare materials, pretreat the materials, make soup and thicken the soup; a step of preparing uncongealed beancurd, which is to prepare materials, soak, grind into thick liquid and make the uncongealed beancurd; and a step of eating, which is to prepare and season the materials. The obtained seafood-marinade uncongealed beancurd is the soy food made by taking peeled shrimps, ham, sea cucumbers, squid and soy as main raw materials mixed with a small amount of seasoning. The appearance of the product is that a lower layer is solid beancurd in white and an upper layer is thick liquid seafood marinade in light yellow. The beancurd is white and soft, and the seafood marinade is aromatic and delicious. The uncongealed beancurd eaten after meals has the function of sobering up, eliminating fatness and promoting digestion.
The subject invention provides methods for making ligand upregulatable G-protein coupled receptors (GPCRs). Ligand upregulatable GPCRs contain a modified TM5-IC3-TM6 segment, which provides for increased levels of the ligand upregulatable GPCR in a host cell in the presence of a ligand as compared to the absence of the ligand. The subject invention also provides assays for screening test compounds for a ligand of a GPCR using a ligand upregulatable GPCR. In these assays, a ligand upregulatable GPCR is contacted with a test compound, and an increase in the detectable amount of the ligand upregulatable GPCR in the host cell indicates that the test compound is a ligand of the GPCR. Said indicated ligands encompass modulators of the GPCR. Said modulators of the GPCR are particularly useful in treating GPCR-related conditions.
The present study aims to predict energy expenditure models for some resistance training exercises like: dumbbell bent row over, dumbbell deadlift, dumbbell lunge, dumbbell shoulder press, and dumbbell squat using oxygen consumption or Metabolic Equivalents (METs) as a dependent variable while blood pressure, heart rate, respiratory exchange ratio, blood lactate, rate of perceived exertion, body mass index, body weight, body height, body fat composition, muscle strength, and surface electromyography of selected muscles as independent variables. The previous literature measures energy expenditure for various lower and upper body resistance training exercises but it devoid for dumbbell bent row over, dumbbell deadlift, dumbbell lunge, dumbbell shoulder press, and dumbbell squat energy expenditure models between untrained and trained participants. The subject will come for 5-8 times clinical trial for total 10-20 days. After the completion of this study, the participant will know about their energy expenditure during included strength training exercises.

The study will include total 30 participants; 15 normal healthy young individuals and 15 athletes with regular resistance exercise training experience. The experiments will be divided into 2 stages. The first stage experiment will be conducted in 10 young individuals into two groups. The group one (untrained) will include 5 normal healthy individuals without resistance exercise training experience and group two (trained) will include 5 individuals with regular resistance training experience of two months. The second stage will proceed more 20 young participants (10 participants in each group) to determine the resistance exercise energy expenditure.
PURPOSE: An injectable polymer formulation including a specific gene complex is provided to have a passive urinary incontinence treatment effect with a polymer mixture matrix including micro particles in the early stage of injection, and to induce stable and continuous production/emission by including a specific gene complex capable of regenerating damaged sphincter, blood vessel and nerve near urethra. CONSTITUTION: An injectable polymer formulation includes a gene complex and a polymer mixture matrix. The gene complex is sustained-released from the polymer mixture matrix. The gene complex includes cationic polymer and plasmid DNA (pDNA) capable of producing a bioactive substance by being introduced into the cell. The bioactive substance is continuously produced and released from the introduced cell. [Reference numerals] (AA) Normal group; (BB) Control group; (CC) Comparative example 1; (DD) Example 1
Do not abruptly discontinue nebivolol therapy in patients with coronary artery disease. Severe exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following the abrupt discontinuation of therapy with β-blockers.

Myocardial infarction and ventricular arrhythmias may occur with or without preceding exacerbation of the angina pectoris. Caution patients without overt coronary artery disease against interruption or abrupt discontinuation of therapy. As with other β-blockers, when discontinuation of nebivolol is planned, carefully observe and advise patients to minimize physical activity.Taper nebivolol over 1 to 2 weeks when possible. If the angina worsens or acute coronary insufficiency develops, re-start nebivolol promptly, at least temporarily.
The purpose of this study is to compare the use of a conventional dose computed tomography scan (C-CT) to a simulated low dose computed tomography scan (L-CT) for preoperative planning in patients who are anticipated to undergo a total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty (RSA) with the goal to reduce the radiation exposure to future patients undergoing preoperative planning. L-CT scans for analysis will be obtained prospectively as derived data from a C-CT scan performed on a dual source CT scanner. Briefly, a C-CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both). For additional validation, prospectively collected scans will be compared to retrospectively gathered scans of patients of similar demographics (age, sex, BMI) and degenerative changes who underwent a C-CT scan for an anticipated shoulder arthroplasty in the past. The reviewers will investigate the following outcome measures including 1) Are L-CT images of sufficient quality to be used for preoperative planning 2) Can accurate measurements including glenoid inclination, version, implant selection and humeral head subluxation be made on L-CT images 3) Do proposed treatment plans change with the use of L-CT relative to the chosen plans base on C-CT images. The investigators hypothesize L-CT images will be of sufficient image quality for diagnostic purposes, with similar measurements, and treatment outcomes.
Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.
EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
In this study, 30 type 2 diabetic patients requiring oral hypoglycemic therapy with Metformin and/or Thiazolidinedione will be randomized. Twenty (20) patients will be randomized to receive active study medication and 10 patients will be randomized to receive vehicle control. After undergoing screening procedures, potential patients will enter a 14 day baseline phase where baseline data will be collected. Pending successful completion of the baseline phase, patient will enter a 28-day treatment phase where they will be randomized to receive either once daily subcutaneous injections of E1 plus G1, as separate injections or once daily subcutaneous injections of vehicle control (as 2 separate injections). Patients will receive once daily doses in the morning after breakfast for a period of 28 days. Upon completion of treatment, all patients will continue in the follow-up phase for an additional 6 months and will return to the clinic for monthly visits. Throughout the study, patients will remain on their current oral hypoglycemic therapy with Metformin and/or Thiazolidinedione and will maintain a diary record of blood glucose levels.

The body's ability to control glucose will be assessed by oral glucose tolerance test (OGTT). After an overnight fast, patients will be asked to drink a solution containing a known amount of glucose. Blood samples for glucose and insulin measurements will be obtained before the patients drink the glucose solution, and again 30 minutes, 60 minutes and 2 hours after the glucose is consumed. This test will be performed at frequent intervals during the study.
Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR \> 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
Participants in the control group performed one session of 80% 1RM without PBFR. The number of repetitions in every set was 10 times.
Included 20 recently diagnosed type 2 diabetic subjects. They all received sitagliptin 100 mg therapy once daily before breakfast.
PROBLEM TO BE SOLVED: To obtain a composition that is useful as an emulsifier, a detergent, a protective colloid agent or a cosmetic base material, particularly as a shampoo by using a novel ester of trehalose of high stability showing reduced change with time as an active ingredient. SOLUTION: This composition is obtained by using, as an active ingredient, a trehalose alkenylsuccinate salt prepared by reaction of trehalose with an alkenylsuccinic anhydride in the presence of an alkali catalyst. This shampoo composition (in an amount of 0.1-65 wt.%) is mixed with an anionic surfactant (1.5-20 wt.%), a cationized polymer (0.1-5 wt.%) and water (the rest totally accounting for <=100 wt.%). In preferred embodiments, an amphoteric surfactant (<=20 wt.%), a nonionic surfactant (<=5 wt.%) and a cationic surfactant (<=5 wt.%) are added to this composition. The composition containing a trehalose alkenylsuccinate salt is excellent in emulsification, foaming power and foam stability. In addition, this ester is readily biodegradable.